Hormonal therapy plus radiation improves prostate cancer survival

Short-term hormonal therapy increases overall survival in patients with prostate cancer, according to a study presented at the 2010 Genitourinary Cancers Symposium.

For the study, David McGowan, MD, of the Cross Cancer Institute in Edmonton, Alberta, and colleagues followed 1,979 men who were randomized to hormonal therapy plus radiation or radiation therapy alone. Men treated with the combination therapy received 4 months of total androgen suppression given prior to and during radiation therapy.

Follow-up after 12 years revealed that the overall survival in the hormone-plus-radiation group was 51% compared to 46% in the radiation-only group. Furthermore, upon rebiopsy, 78% of biopsies from patients in the hormone-plus-radiation group were negative, whereas 60% of  biopsies were cancer-free among patients in the radiation-only group.

“There doesn't seem to be any disadvantage to the addition of hormonal treatment to radiation,” Dr. McGowan concluded. “We can recommend the use of hormonal therapy with radiation in high-risk and intermediate-risk patients, but not for low-risk patients.”

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs